Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal health care system.
Indigenous
disparities in health
outcomes
prostate cancer
screening
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
revised:
22
02
2023
received:
09
01
2023
accepted:
24
02
2023
medline:
21
8
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
ppublish
Résumé
Indigenous Peoples have higher morbidity rates and lower life expectancies than non-Indigenous Canadians. Identification of disparities between Indigenous and non-Indigenous men regarding prostate cancer (PCa) screening, diagnoses, management, and outcomes was sought. An observational cohort of men diagnosed with PCa between June 2014 and October 2022 was studied. Men were prospectively enrolled in the province-wide Alberta Prostate Cancer Research Initiative. The primary outcomes were tumor characteristics (stage, grade, and prostate-specific antigen [PSA]) at diagnosis. Secondary outcomes were PSA testing rates, time from diagnosis to treatment, treatment modality, and metastasis-free, cancer-specific, and overall survivals. Examination of 1,444,974 men for whom aggregate PSA testing data were available was performed. Men in Indigenous communities were less likely to have PSA testing performed than men outside of Indigenous communities (32 vs. 46 PSA tests per 100 men [aged 50-70 years] within 1 year; p < .001). Among 6049 men diagnosed with PCa, Indigenous men had higher risk disease characteristics: a higher proportion of Indigenous men had PSA ≥ 10 ng/mL (48% vs. 30%; p < .01), TNM stage ≥ T2 (65% vs. 47%; p < .01), and Gleason grade group ≥ 2 (79% vs. 64%; p < .01) compared to non-Indigenous men. With a median follow-up of 40 months (interquartile range, 25-65 months), Indigenous men were at higher risk of developing PCa metastases (hazard ratio, 2.3; 95% CI, 1.2-4.2; p < .01) than non-Indigenous men. Despite receiving care in a universal health care system, Indigenous men were less likely to receive PSA testing and more likely to be diagnosed with aggressive tumors and develop PCa metastases than non-Indigenous men.
Sections du résumé
BACKGROUND
Indigenous Peoples have higher morbidity rates and lower life expectancies than non-Indigenous Canadians. Identification of disparities between Indigenous and non-Indigenous men regarding prostate cancer (PCa) screening, diagnoses, management, and outcomes was sought.
METHODS
An observational cohort of men diagnosed with PCa between June 2014 and October 2022 was studied. Men were prospectively enrolled in the province-wide Alberta Prostate Cancer Research Initiative. The primary outcomes were tumor characteristics (stage, grade, and prostate-specific antigen [PSA]) at diagnosis. Secondary outcomes were PSA testing rates, time from diagnosis to treatment, treatment modality, and metastasis-free, cancer-specific, and overall survivals.
RESULTS
Examination of 1,444,974 men for whom aggregate PSA testing data were available was performed. Men in Indigenous communities were less likely to have PSA testing performed than men outside of Indigenous communities (32 vs. 46 PSA tests per 100 men [aged 50-70 years] within 1 year; p < .001). Among 6049 men diagnosed with PCa, Indigenous men had higher risk disease characteristics: a higher proportion of Indigenous men had PSA ≥ 10 ng/mL (48% vs. 30%; p < .01), TNM stage ≥ T2 (65% vs. 47%; p < .01), and Gleason grade group ≥ 2 (79% vs. 64%; p < .01) compared to non-Indigenous men. With a median follow-up of 40 months (interquartile range, 25-65 months), Indigenous men were at higher risk of developing PCa metastases (hazard ratio, 2.3; 95% CI, 1.2-4.2; p < .01) than non-Indigenous men.
CONCLUSIONS
Despite receiving care in a universal health care system, Indigenous men were less likely to receive PSA testing and more likely to be diagnosed with aggressive tumors and develop PCa metastases than non-Indigenous men.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2864-2870Informations de copyright
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Prostate Cancer Statistics. Canadian Cancer Statistics Advisory Committee, Canadian Cancer Society. Accessed December 18, 2021. https://cancer.ca/en/cancer-information/cancer-types/prostate/statistics
Wong ECL, Kapoor A. Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: a systematic review. Can Urol Assoc J. 2017;11(5):E222. doi:10.5489/cuaj.4185
Withrow DR, Pole JD, Nishri ED, Tjepkema M, Marrett LD. Cancer survival disparities between First Nation and non-Aboriginal adults in Canada: follow-up of the 1991 Census Mortality Cohort. Cancer Epidemiol Biomarkers Prev. 2017;26(1):145-151. doi:10.1158/1055-9965.epi-16-0706
King M. Chronic diseases and mortality in Canadian Aboriginal peoples: learning from the knowledge. Prev Chronic Dis. 2011;8(1):A07.
Cameron BL, Carmargo Plazas MdP, Salas AS, Bourque Bearskin RL, Hungler K. Understanding inequalities in access to health care services for Aboriginal people: a call for nursing action. Adv Nurs Sci. 2014;37(3):E1-E16. doi:10.1097/ans.0000000000000039
Nelson SE, Wilson K. Understanding barriers to health care access through cultural safety and ethical space: Indigenous people’s experiences in Prince George, Canada. Soc Sci Med. 2018;218:21-27. doi:10.1016/j.socscimed.2018.09.017
Vasquez C, Kolinsky M, Djebah R, et al. Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada. BMJ Open. 2020;10(10):e037222. doi:10.1136/bmjopen-2020-037222
Rendon RA, Mason RJ, Marzouk K, et al. Canadian Urological Association recommendations on prostate cancer screening and early diagnosis. Can Urol Assoc J. 2017;11(10):298-309. doi:10.5489/cuaj.4888
Addressing Guidelines. Canada Post. Accessed July 26, 2022. https://www.canadapost-postescanada.ca/cpc/en/support/articles/addressing-guidelines/postal-codes.page#:~:text=code%20searching%20tools-,The%20structure%20of%20the%20postal%20code,Local%20Delivery%20Unit%20(LDU)
Dess RT, Hartman HE, Mahal BA, et al. Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 2019;5(7):975-983. doi:10.1001/jamaoncol.2019.0826
Stern N, Ly TL, Welk B, et al. Association of race and ethnicity with prostate cancer-specific mortality in Canada. JAMA Netw Open. 2021;4(12):e2136364. doi:10.1001/jamanetworkopen.2021.36364
Focus on Geography Series, 2016 Census. Catalog number 98-404-X2016001. Statistics Canada. February 8, 2017. Accessed December 10, 2022. https://www12.statcan.gc.ca/census-recensement/2016/as-sa/fogs-spg/Index-eng.cfm
Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532-2542. doi:10.1001/jama.2017.7248